Interleukin-13 Antagonist

Interleukin-13 Antagonists

Dermatitis, Atopic

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Tralokinumab-ldrm, an interleukin-13 antagonist, is a human IgG4 monoclonal antibody. Tralokinumab-ldrm is produced in mouse myeloma cells by recombinant DNA technology, consists of 1326 amino acids, and has a molecular weight of approximately 147 kilodaltons.</p><p>ADBRY (tralokinumab-ldrm) injection is a sterile, preservative-free, clear to opalescent, colorless to pale yellow solution for subcutaneous use supplied as either a single-dose prefilled syringe with needle guard in a siliconized Type-1 clear glass syringe or a single-dose autoinjector with a siliconized Type-1 clear glass syringe inside. None of the components of the prefilled syringe, autoinjector or the needle guard are made with natural rubber latex.</p><p>Each prefilled syringe delivers 150 mg tralokinumab-ldrm in 1 mL and the inactive ingredients: acetic acid (0.3 mg), polysorbate 80 (0.1 mg), sodium acetate trihydrate (6 mg), sodium chloride (5 mg), and Water for Injection, at an approximate pH of 5.5.</p><p>Each autoinjector delivers 300 mg tralokinumab-ldrm in 2 mL and the inactive ingredients: acetic acid (0.6 mg), polysorbate 80 (0.2 mg), sodium acetate trihydrate (12 mg), sodium chloride (10 mg), and Water for Injection, at an approximate pH of 5.5.</p></section>

Adbry

tralokinumab

tralokinumab-ldrm

1 ML tralokinumab-ldrm 150 MG/ML Prefilled Syringe

1 ML tralokinumab-ldrm 150 MG/ML Prefilled Syringe [Adbry]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Adbry is a prescription medication used to treat adults who have moderate-to-severe eczema that is not controlled well by topical prescription therapies or for those who cannot use topical therapies. It can be used with or without topical corticosteroids.

Adbry is FDA approved for the following indications: Atopic Dermatitis 

Report Adverse Event

Prescribing Information

Medication Guide 

Pharmacy List 

Coverage Authorization Request

Coverage Authorization Appeals 

Letter of Medical Necessity

Letter of Medical Exception

Adbry Advocate Enrollment Form 

Adbry Advocate Enrollment Form - Spanish

Enroll in Patient Savings Program 

Bridge Program 

Adbry Patient Assistance Program 

Adbry Rapid Start Program 

Other HCP Resources 

About Adbry

Side Effects 

Taking Adbry

FAQs: Atopic Dermatitis

Adbry Advocate Program 

App Download - iOS

App Download - Android

Patient Brochure 

Instructions For Use: Atopic Dermatitis 